Actively Recruiting
Current Status of BTKi Treatment for CLL/SLL in China
Led by The First Affiliated Hospital with Nanjing Medical University · Updated on 2024-07-18
1000
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
BTKi has become the standard treatment regimen for CLL/SLL，there is a lack of large-scale real-world studies on the use status and related influencing factors of BTK inhibitors. Therefore, we plan to conduct this multicenter retrospective cross-sectional study to understand the current situation of BTK inhibitor treatment for CLL/SLL patients in China and the related influencing factors, and to explore more suitable treatment patterns based on this.
CONDITIONS
Official Title
Current Status of BTKi Treatment for CLL/SLL in China
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 63 18 years
- Patients with a confirmed diagnosis of CLL/SLL
- Received BTK inhibitor treatment between February 2023 and February 2024
You will not qualify if you...
- Patients with other types of lymphoma
- Cases deemed unsuitable for inclusion in this study by the investigators
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Haematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital
Nanjin, Jiangsu, China, 210029
Actively Recruiting
Research Team
H
Huayuan Zhu, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here